Scatter factor receptor (c-Met) as possible prognostic factor in patients with oral squamous cell carcinoma.

This report was performed to study the biological role of c-Met in oral tumorigenesis by analyzing its expression in relation to clinicopathological features. Seventy-three cases of oral squamous cell carcinoma and 10 of normal mucosa were analysed for c-Met expression by immunohistochemistry. Normal oral squamous epithelium showed absent or low membranous positivity in the intermediate (malpighian-spinous) layer. Fifty-seven cases (78%) of carcinoma showed immunopositivity, with a prevalently membranous positivity and scattered areas also showing a cytoplasmic localization. Sixteen cases of carcinoma (22%) showed no positivity for c-Met. Among positive tumours, well-differentiated areas showed low or absent cytoplasmic positivity, while low-differentiated areas showed both membranous and cytoplasmic positivity. There was no statistically significant correlation between c-Met expression and sex, recurrence, staging or grading. The frequency of lymph node metastases was higher in c-Met-positive tumours (17/57, 29%) than in c-Met-negative ones (4/16, 25%). When analysed for prognostic significance, patients with negative/reduced c-Met expression had better survival rates than patients with high expression. The difference between survival rates was statistically significant (p<0.05). These data suggest that c-Met expression may be useful to identify cases of oral squamous cell carcinoma with a more aggressive and invasive phenotype.

[1]  S. Giordano,et al.  MET receptor is overexpressed but not mutated in oral squamous cell carcinomas , 2001, Journal of cellular physiology.

[2]  S. Law,et al.  Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  T. Aso,et al.  Hepatocyte growth factor/scatter factor is implicated in the mode of stromal invasion of uterine squamous cervical cancer. , 2001, Gynecologic oncology.

[4]  M. Hoque,et al.  Role of HGF/c‐met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance , 2001, International journal of cancer.

[5]  C. Van Waes,et al.  Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. , 2001, Cancer research.

[6]  P. Comoglio,et al.  Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases , 2000, International journal of cancer.

[7]  Nakopoulou,et al.  c‐met tyrosine kinase receptor expression is associated with abnormal β‐catenin expression and favourable prognostic factors in invasive breast carcinoma , 2000, Histopathology.

[8]  P. Comoglio,et al.  Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas , 2000, Oncogene.

[9]  C. Birchmeier,et al.  Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. , 1998, Trends in cell biology.

[10]  M. Tsao,et al.  The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). , 1998, Oncology reports.

[11]  Darby D. Marshall,et al.  Overexpression of scatter factor and its receptor (c‐met) in oral squamous cell carcinoma , 1998, The Laryngoscope.

[12]  O. Tokunaga,et al.  Expression of c-Met in laryngeal carcinoma , 1998, Virchows Archiv.

[13]  S. Ménard,et al.  A point mutation in the MET oncogene abrogates metastasis without affecting transformation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Bardelli,et al.  "Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection. , 1997, Biochimica et biophysica acta.

[15]  P. Lollini,et al.  Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. , 1996, Oncogene.

[16]  W. Birchmeier,et al.  Hepatocyte growth factor/scatter factor induces a variety of tissue- specific morphogenic programs in epithelial cells , 1995, The Journal of cell biology.

[17]  Carmen Birchmeier,et al.  Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud , 1995, Nature.

[18]  L. Donehower,et al.  Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. , 1995, Cancer research.

[19]  M. Sharpe,et al.  Scatter factor/hepatocyte growth factor is essential for liver development , 1995, Nature.

[20]  Tetsuo Noda,et al.  Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor , 1995, Nature.

[21]  K. Matsumoto,et al.  Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. , 1994, The Journal of biological chemistry.

[22]  G. V. Vande Woude,et al.  Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Comoglio,et al.  Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. , 1993, British Journal of Cancer.

[24]  C. Birchmeier,et al.  Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development , 1993, The Journal of cell biology.

[25]  M. Pierotti,et al.  Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. , 1992, Oncogene.

[26]  L. Naldini,et al.  Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth , 1992, The Journal of cell biology.

[27]  G. V. Vande Woude,et al.  The met proto-oncogene receptor and lumen formation. , 1992, Science.

[28]  E Medico,et al.  Expression of the Met/HGF receptor in normal and neoplastic human tissues. , 1991, Oncogene.

[29]  N. Fausto.  Hepatocyte growth factor receptor and the c-met oncogene Bottaro DP, Rubin JS, Faletto DL, Chan AM-L, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802?804 , 1991 .

[30]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[31]  G. V. Vande Woude,et al.  Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[32]  S. Schnitt,et al.  Expression of scatter factor and c-met receptor in benign and malignant breast tissue. , 1997, Cancer.

[33]  P. Comoglio,et al.  Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. , 1997, European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery.

[34]  B. Elliott,et al.  Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. , 1996, The American journal of pathology.